BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25266309)

  • 21. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
    Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
    J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.
    Hanley PJ; Lam S; Shpall EJ; Bollard CM
    J Vis Exp; 2012 May; (63):e3627. PubMed ID: 22588077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
    Sun Q; Pollok KE; Burton RL; Dai LJ; Britt W; Emanuel DJ; Lucas KG
    Blood; 1999 Nov; 94(9):3242-50. PubMed ID: 10556213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.
    Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM
    J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
    Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
    Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
    Rooney CM; Smith CA; Ng CY; Loftin SK; Sixbey JW; Gan Y; Srivastava DK; Bowman LC; Krance RA; Brenner MK; Heslop HE
    Blood; 1998 Sep; 92(5):1549-55. PubMed ID: 9716582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
    Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
    Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
    Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
    Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.
    Savoldo B; Heslop HE; Rooney CM
    Leuk Lymphoma; 2000 Nov; 39(5-6):455-64. PubMed ID: 11342329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors.
    Orentas RJ; Lemas MV; Mullin MJ; Colombani PM; Schwarz K; Ambinder R
    J Hematother; 1998 Jun; 7(3):257-61. PubMed ID: 9621259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
    Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
    J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr virus-related lymphoproliferative disease complicating childhood acute lymphoblastic leukemia: no recurrence after unrelated donor bone marrow transplantation.
    Pondarré C; Kebaili K; Dijoud F; Basset T; Philippe N; Bertrand Y
    Bone Marrow Transplant; 2001 Jan; 27(1):93-5. PubMed ID: 11244444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
    Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
    Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens.
    Niederwieser D; Grassegger A; Auböck J; Herold M; Nachbaur D; Rosenmayr A; Gächter A; Nussbaumer W; Gaggl S; Ritter M
    Blood; 1993 Apr; 81(8):2200-8. PubMed ID: 8471780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.
    Falkenburg JH; Faber LM; van den Elshout M; van Luxemburg-Heijs SA; Hooftman-den Otter A; Smit WM; Voogt PJ; Willemze R
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):305-9. PubMed ID: 8280712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
    Heslop HE; Rooney CM
    Immunol Rev; 1997 Jun; 157():217-22. PubMed ID: 9255632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.